熱門資訊> 正文
MNPR-101-ZR第一阶段数据显示Monopar股价上涨60%
2024-09-12 23:05
- Shares of Monopar Therapeutics (NASDAQ:MNPR) rallied 60% early Thursday after the company reported positive Phase 1 data for MNPR-101-Zr, a zirconium-89 imaging radioisotope conjugated to its monoclonal antibody therapy MNPR-101.
- The Phase 1 imaging and dosimetry clinical trial is aimed at confirming MNPR-101-Zr’s tumor targeting ability in humans. MNPR-101 is targeted at tumors expressing uPAR, which includes a majority of triple-negative breast, colorectal, bladder, ovarian, gastric and pancreatic cancers.
More on Monopar Therapeutics
- Seeking Alpha’s Quant Rating on Monopar Therapeutics
- Historical earnings data for Monopar Therapeutics
- Financial information for Monopar Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
